Endpoint
Macular pigment optical density
CAT:outcome/macular-pigment-optical-densityreported in optical density units3 findings from 1 compound
What moved it
How to read these marks3 findings · 1 compound · by evidence strength
| Compound | Direction | Findings | Strongest evidence |
|---|---|---|---|
| lutein | up | 3 | Evidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers. |
Reported to move it
3 findings
lutein — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“This meta-analysis revealed that lutein, zeaxanthin and meso-zeaxanthin supplementation improved MPOD both in AMD patients and healthy subjects with a dose-response relationship.”
Quoted verbatim from Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density.. - Study
- meta-analysis
- Population
- Age-related macular degeneration patients and healthy subjects, pooled RCTs. Combined lutein/zeaxanthin/meso-zeaxanthin intervention.
Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density.2016PMID:27420092Permalink
lutein — increases
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×2“The LZ group showed significant increases in MPOD at all visits post-supplementation, with significant increases as early as day 42 compared to placebo.”
Quoted verbatim from Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study.. - Study
- RCT
- Duration
- 6 months
- Dose
- gummies containing 10 mg lutein and 2 mg zeaxanthin daily for 180 days
- Population
- children aged 5-12 years
Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study.2024PMID:38363462An author is affiliated with a producerPermalink
lutein — increases
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Findingreplicated ×2“It has been found that lutein treatment was associated with a significant improvement in MPOD, with mean differences between lutein and placebo groups in the changes from baseline of 0.09 (95% CI: 0.06, 0.12; p < 0.00001).”
Quoted verbatim from Role of lutein supplementation in the management of age-related macular degeneration: meta-analysis of randomized controlled trials.. - Study
- meta-analysis
- Population
- AMD patients or individuals at risk of AMD
Role of lutein supplementation in the management of age-related macular degeneration: meta-analysis of randomized controlled trials.2014PMID:25358528Permalink
How it is measured
Macular pigment optical density by heterochromatic flicker photometry, fundus autofluorescence or reflectometry, at the retinal eccentricity the study states. The method and eccentricity are recorded with each finding where the source supplies them.
Measured, not recorded
- Subject
- macular pigment optical density
- Measurements
- 1 measurement
- Recorded as a finding
- No
Show what was measured
macular pigment optical density
At baseline, the MPOD in AMD patients with placebo was 0.286 ± 0.017 meanwhile in AMD patients with supplementation it was 0.291 ± 0.016
PMID:23434908 · one of two readings recorded this
Sources cited
3 papers
- Subject
- macular pigment optical density
- Findings
- 3
- Papers
- 3
Lutein and Zeaxanthin Supplementation Improves Dynamic Visual and Cognitive Performance in Children: A Randomized, Double-Blind, Parallel, Placebo-Controlled Study.record2024PMID:383634621 finding
Lutein, Zeaxanthin and Meso-zeaxanthin Supplementation Associated with Macular Pigment Optical Density.record2016PMID:274200921 finding
Role of lutein supplementation in the management of age-related macular degeneration: meta-analysis of randomized controlled trials.record2014PMID:253585281 finding